Pelthos Therapeutics Inc.
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
PTHS$8.90-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| For the Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||
| Net loss | $(1,967,611) | $(2,562,330) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Amortization of debt discount | 94,213 | 605,630 |
| Stock-based compensation | 485,831 | 292,552 |
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued expenses | 706,478 | 90,994 |
| Accrued compensation | — | (152,023) |
| Due from Chromocell Corporation | — | (45,786) |
| Prepaid expenses | 48,963 | (220,930) |
| Net Cash Used In Operating Activities | (632,126) | (1,991,893) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||
| Proceeds from loan payable, net of debt discount | 250,000 | — |
| Payment of bridge loan, net of debt discount | — | (214,757) |
| Common stock issued for cash | — | 5,972,000 |
| Recission of common stock | — | (91,512) |
| Net Cash Provided By Financing Activities | 250,000 | 5,665,731 |
| NET CHANGE IN CASH | (382,126) | 3,673,838 |
| CASH AT BEGINNING OF YEAR | 513,443 | 96,391 |
| CASH AT END OF YEAR | $131,317 | $3,770,229 |
| Supplemental cash flow information: | ||
| Cash paid for income taxes | $— | $— |
| Cash paid for interest expense | $11,250 | $— |
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||
| Debt discount from common stock issued for extension of bridge loan | $— | $447,779 |
| Conversion of notes to common stock | $— | $1,362,821 |
| Transfer of liabilities to Chromocell Corporation for Series C Preferred Stock | $— | $2,153,362 |
| Offering costs recorded to debt discount | $26,875 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.